ADT + enzalutamide (continuous)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LEUPROLIDE` `DRUG-ENZALUTAMIDE`

ID	`REG-ADT-ENZALUTAMIDE`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Notes

ENZAMET established benefit in mHSPC. PREVAIL: 1L mCRPC vs ADT-mono. AFFIRM: post-docetaxel mCRPC. Most CNS penetration of ARPIs — cognitive AEs more common in elderly.

Used By

Contraindications

CI-PROSTATE-SEIZURE-HISTORY-ENZALUTAMIDE - CI-PROSTATE-SEIZURE-HISTORY-ENZALUTAMIDE

Handbook Chapters

HB-PROSTATE-MCRPC-1L - Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning

Indication

IND-PROSTATE-MCRPC-1L-ARPI - IND-PROSTATE-MCRPC-1L-ARPI